Bruker Corporation (BRKR) Valuation
Historical valuation analysis based on 500 data points (2024-09-23 to 2026-09-21)
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segme...
Bruker Corporation (BRKR) currently trades at a P/E ratio of 58.89 (historical range: 24.19–83.78, median: 55.32), placing it at the 58th percentile — near its historical average, P/S ratio of 2.72 (range: 1.29–4.10, 84th percentile — expensive relative to its history), EV/EBITDA of 234.79 (range: 21.55–243.83, 98th percentile).
Over the historical period (2024-09-23 to 2026-09-21), Bruker Corporation's P/E ratio has expanded by 12% over the observed period (from an average of 54.0 to 60.3).
Bruker Corporation trades well above its own historical valuation range across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 58.89 | 24.19 | 55.32 | 83.78 | 58th | near its historical average |
| P/S Ratio | 2.72 | 1.29 | 1.98 | 4.10 | 84th | expensive relative to its history |
| EV/EBITDA | 234.79 | 21.55 | 47.79 | 243.83 | 98th | expensive relative to its history |
| FCF Yield | 0.01 | 0.01 | 0.01 | 0.03 | 2th | expensive relative to its history |
Bruker Corporation (BRKR) Valuation & P/E History
Bruker Corporation (BRKR) is a US-listed stock operating in the Technology sector, specifically the Laboratory Analytical Instruments industry currently trading at $61.22 with a market capitalization of $9.3 billion. This page provides historical valuation analysis for BRKR based on 500 data points covering 2024-09-23 to 2026-09-21. The P/E ratio of 58.89 is above the historical median of 55.32, placing BRKR at the 58th percentile of its valuation range. The P/S ratio of 2.72 compares to a median of 1.98.
BRKR Valuation Metrics & Historical Range
The valuation table above shows Bruker Corporation's current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether BRKR is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests BRKR is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Bruker Corporation.
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is BRKR Overvalued or Undervalued?
Bruker Corporation trades well above its own historical valuation range across most metrics. The overall valuation percentile of 80 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive BRKR is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full BRKR analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.BRKR trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.